CAC to be acquired by AAIPharma
AAIPharma is to acquire Cvitkovic & Associes Consultants (CAC), an international contract research organisation specialising in oncology drug development and medical consulting.
AAIPharma is to acquire Cvitkovic & Associes Consultants (CAC), an international contract research organisation specialising in oncology drug development and medical consulting.
The acquisition of CAC provides AAIPharma with additional therapeutic expertise, while further strengthening its global clinical development business.
With over ten years of international experience in all clinical phases of oncology drug development, CAC has extensive experience in performing lead assessment of new analogues of established drugs as well as novel target-oriented compounds.
The company has developed expertise in a wide range of cancer therapies, including cytotoxics, cytostatics, monoclonal antibodies, cell-based therapies, vaccines, antiangiogenic agents, apoptosis inducers and hormonal therapies.
CAC is headquartered in Paris, France, and has offices in the US, Europe, and Latin America.
The acquisition, which is expected to close in the fourth quarter of 2006, is subject to customary closing conditions. Terms of the all cash transaction have not been disclosed.